{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-177406","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2026-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.295584+00:00","generated_at":"2026-05-15T04:15:14.197779+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"NewAmsterdam Pharma CAO Louise Kooij to depart Aug 31, 2026; severance terms set","bullets":["Louise Kooij to step down as Chief Accounting Officer effective August 31, 2026.","Separation agreement includes 12 months base salary lump sum and pro-rated 2026 bonus.","Vesting of outstanding stock options and RSUs extended to Jan 10, 2027; exercise period to Feb 10, 2027.","Agreement includes confidentiality, non-compete, non-disparagement covenants and claims release."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-177406","json":"https://secwatch.observer/filing/0001193125-26-177406.json","markdown":"https://secwatch.observer/filing/0001193125-26-177406.md","text":"https://secwatch.observer/filing/0001193125-26-177406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526177406/0001193125-26-177406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526177406/nams-20260420.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:15:14.197779+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}